NovAliX, a contract research organisation focused on medication discovery, has revealed their collaboration with Sanofi to create novel DNA-Encoded Libraries (DELs).
Global head of integrated drug discovery at Sanofi, John Macor, said that “This partnership with NovAliX will allow Sanofi to accelerate its transition in revolutionary screening technology by creating our own Sanofi-owned DNA-encoded library, significantly boosting our development of innovative healthcare solutions,”
“This partnership with NovAliX will allow Sanofi to accelerate its transition in revolutionary screening technology“
Chief Executive Officer at NovAliX, Denis Zeyer, explained how “Throughout our long history in chemobiological screening techniques, we have always championed the potential of DEL technology. We see this agreement with Sanofi as a vindication of our belief; demonstrating the quality of our platform and the interest that the pharmaceutical sector has in this technology, which can be used to create new chemical diversities and to screen at a very high throughput.”
NovAliX put €5.3 million into the development of its DEL platform in December of last year. The NovAliX and Sanofi collaboration agreement will entail knowledge synergies between the two companies' specialists. The collaboration is projected to create the production of approximately fifty chemical libraries with 1.5 billion compounds.